Skip to content
drillr.ai

PTGX

Protagonist Therapeutics, Inc.

NASDAQ · USHealthcareBiotechnology
$134.27-4.71%

Price as of Jul 20, 2026

PTGX news

Protagonist Therapeutics, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Protagonist Therapeutics Reports Granting of Inducement Awards

    NEWARK, CA / ACCESS Newswire (https://www.accessnewswire.com/) / July 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on July 15, 2026, it granted inducement awards to three recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022. The new employees received

    ACCESSWIRE ·

  2. Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress

    NEWARK, CA / ACCESS Newswire (https://www.accessnewswire.com/) / June 1, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that four abstracts highlighting rusfertide in polycythemia vera (PV) will be presented at the 2026 European Hematology Association Congress (EHA2026 Congress), taking place June 11-14, 2026, in Stockholm, Sweden. The presentations include analyses from the randomized, controlled Phase 3 VERIFY study, as well as long-term results from the

    ACCESSWIRE ·

  3. Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026

    NEWARK, CA / ACCESS Newswire (https://www.accessnewswire.com/) / May 28, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in two investment bank conferences taking place in June 2026. 2026 Jefferies Global Healthcare Conference; New York, NY - June 2-4, 2026 Format: Fireside Chat Day/Time: Wednesday, June 3 at 9:55 A.M. ET Webcast: https://event.summitcast.com/vi

    ACCESSWIRE ·

  4. Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration

    Opt-out election makes Protagonist eligible for $200 million upon exercise and an additional $200 million upon FDA approval of rusfertide for polycythemia vera Approval would also trigger a $75 million milestone payment, bringing total potential cash tied to the opt-out election and approval to $475 million Protagonist becomes eligible for up to $975 million in milestone payments and tiered royalties ranging from 14% to 29% on worldwide net sales NEWARK, CA / ACCESS Newswire (https://www.acce

    ACCESSWIRE ·

  5. Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting

    One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasis Results further support the differentiated profile of ICOTYDE, the first and only IL-23 receptor targeted oral peptide NEWARK, CA / ACCESS Newswire (https://www.accessnewswire.com/) / March 28, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced new one-year Pha

    ACCESSWIRE ·

  6. Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis

    ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill Approval supported by four phase 3 studies that met all primary endpoints and demonstrated a favorable safety profile in 2,500 patients $50 million milestone payment triggered by FDA approval; Protagonist is eligible to receive 6 - 10% royalties on sales and up to $580 million in future milestone payments Webcast and conference call to be held at 8:

    ACCESSWIRE ·

  7. CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    (This release updates the release that posted earlier on February 25, 2026 to update the sub headlines.) NDA for rusfertide submitted to the US Food and Drug Administration (FDA), with potential approval and launch this year Company expects to opt-out of the 50:50 profit and loss sharing arrangement for rusfertide with Takeda during a 90-day window expected to open in Q2 U.S. regulatory decision for ICOTYDE(TM) (icotrokinra) anticipated in 2026 with potential launch this year PN-881 Phase 1 comp

    ACCESSWIRE ·

  8. Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    NDA for rusfertide submitted to the US Food and Drug Administration (FDA), with potential approval and launch this year Company expects to opt-out of the 50:50 profit and loss sharing arrangement for rusfertide with Takeda during a 90-day window expected to open in Q2 U.S. regulatory decision for ICOTYDE(TM) (icotrokinra) anticipated in 2026 with potential launch this year PN-881 Phase 1 completion expected by mid-2026 NEWARK, CALIFORNIA / ACCESS Newswire (https://www.accessnewswire.com/) / Febr

    ACCESSWIRE ·